8 January 2026
Latham & Watkins Advises Leading Stem Cell Biotech Mesoblast on Refinancing of Up to US$125 Million
Advising firms
Deal team
8 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Haim Zaltzman Lead | Latham & Watkins LLP | Partner | finance | Not stated |
| Hyunji Lee | Latham & Watkins LLP | Associate | finance | Not stated |
| William Lane | Latham & Watkins LLP | Associate | finance | Not stated |
| Eric Cho | Latham & Watkins LLP | Partner | tax | Not stated |
| Sam Yang | Latham & Watkins LLP | Associate | tax | Not stated |
| James Chesterman | Latham & Watkins LLP | Partner | finance | Not stated |
| Chris Attrill | Latham & Watkins LLP | Associate | finance | Not stated |
| Kathleen Teo | Latham & Watkins LLP | Associate | finance | Not stated |
Stated terms
- Stated value
- USD 125m (US$125 Million)
- What the figure measures
- Facility amount
- Client
- Mesoblast LimitedBorrower
- Counterparties
- Dr. Gregory George (Lenders)
Oaktree Capital Management, Inc. (Lenders)
NovaQuest Capital Management LLC (Lenders)